首页> 外文期刊>Neurology and therapy. >Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms
【24h】

Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms

机译:老年人口的多药店:通过使用临床决策支持软件平台来加强药物管理

获取原文
           

摘要

IntroductionPolypharmacy is a growing problem in the United States. The use of multiple medications increases the likelihood that a patient will experience potential drug interactions and adverse drug reactions (ADRs). Those individuals with dementia or Alzheimer’s disease (AD) are at greater risk, due to age, comorbidities, and an increased likelihood of being on a greater number of neuroactive medications. MethodsuMETHOD Health (uMH) has developed a precision medicine platform to address dementia and mild AD through the creation of personalized, multidomain treatment plans. Many interactions and ADRs may be observed, such as drug–drug interactions (DDIs), drug–gene interactions (DGIs), anticholinergic cognitive burden (ACB), and depression-inducing drugs (DIDs). uMH’s algorithms can parse these interactions, rate them based on input from open-source databases, and then record all these interactions in a generated treatment plan. A total of 295 individuals aged 65 and older were included in this analysis. ResultsOf 295 individuals, 97.59% were on at least one medication, with an overall mean of 11.5 medications per person; 83.66% were on five or more medications. A total of 102 DGIs, 3642 DDIs, and one high-priority DDI were found in this population. There was a significant increase in the number of DDIs as medications per person increased ( P value??0.0001). Of the population, 65.86% were on one or more anticholinergic drugs. There was a significant difference in the ACB score between individuals with cognitive decline and those without. In total, 60.98% of the overall population were on DIDs, with a mean of 1.19 medications per person. ConclusionsThe results of this work show that older populations have a high medication burden. With the growing elderly and AD populations, medication management for polypharmacy is a need that grows direr every year. uMH’s platform was able to identify a multitude of polypharmacy problems that individuals are currently facing. FundinguMETHOD Health.
机译:简介多元药房在美国是一个日益严重的问题。使用多种药物会增加患者遭受潜在药物相互作用和药物不良反应(ADR)的可能性。那些患有痴呆症或阿尔茨海默氏病(AD)的人由于年龄,合并症以及使用大量神经活性药物的可能性增加,因此处于更大的风险中。方法uMETHOD Health(uMH)开发了一个精确的医学平台,可通过创建个性化的多域治疗计划来解决痴呆和轻度AD。可能会观察到许多相互作用和ADR,例如药物相互作用(DDI),药物基因相互作用(DGI),抗胆碱能认知负担(ACB)和诱导抑郁症的药物(DID)。 uMH的算法可以解析这些相互作用,根据开放源数据库的输入对其进行评分,然后将所有这些相互作用记录在生成的治疗计划中。该分析总共包括295位65岁以上的人。结果在295位患者中,有97.59%的患者至少使用一种药物,平均每人平均使用11.5种药物; 83.66%使用了五种或以上药物。在该人群中总共发现了102个DGI,3642个DDI和一个高优先级DDI。随着人均用药量的增加,DDI的数量显着增加(P值?<?0.0001)。在人口中,有65.86%的人服用一种或多种抗胆碱药。有认知能力减退的人与没有认知能力减退的人之间的ACB评分存在显着差异。总共有60.98%的人接受DID,平均每人使用1.19种药物。结论这项工作的结果表明,老年人口有较高的药物负担。随着老年人和AD人口的增长,对多药店的药物管理的需求逐年增加。 uMH的平台能够识别出个人当前面临的多种多元药房问题。 FundinguMETHOD健康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号